Published in Oncotarget on October 11, 2016
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev (2007) 5.21
Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) (1996) 4.52
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med (1994) 4.46
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood (2012) 3.96
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology (2003) 3.52
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer (2011) 2.36
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 2.15
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell (2015) 2.13
Langerhans cell histiocytosis: Current concepts and treatments. Cancer Treat Rev (2010) 2.07
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study. Virchows Arch (2014) 1.99
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia (2005) 1.95
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol (2010) 1.93
KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol (2006) 1.80
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery (2009) 1.72
Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch (2008) 1.71
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol (2005) 1.66
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol (2004) 1.65
Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res (2009) 1.63
Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod Pathol (2013) 1.59
CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol (2012) 1.51
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab (2010) 1.50
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer (2011) 1.49
Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol (2009) 1.47
Exploiting the bad eating habits of Ras-driven cancers. Genes Dev (2013) 1.45
Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology (2010) 1.44
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol (2016) 1.40
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol (2013) 1.38
Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med (2011) 1.37
BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood (2012) 1.36
Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer (2011) 1.34
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget (2013) 1.32
A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab (2012) 1.30
The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol (2004) 1.24
Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol (2011) 1.23
Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol (2008) 1.21
Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol (2011) 1.17
BRAF in melanoma: current strategies and future directions. Clin Cancer Res (2013) 1.16
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer (2009) 1.13
Clinicopathological relevance of BRAF mutations in human cancer. Pathology (2013) 1.11
Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol (2011) 1.10
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol (2012) 1.08
Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab (2010) 1.07
Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC? Virchows Arch (2014) 1.06
Langerhans cell histiocytosis: old disease new treatment. QJM (2010) 1.04
Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis Markers (2009) 1.01
Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. Am J Surg Pathol (2012) 1.00
Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid (2012) 0.99
Chester-Erdheim disease: a neoplastic disorder. Hum Pathol (1999) 0.99
Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res (2014) 0.98
MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci (2014) 0.97
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev (2014) 0.96
Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark (2010) 0.95
Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res (2008) 0.95
Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov (2014) 0.94
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia (2003) 0.94
Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid (2010) 0.94
Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol (2014) 0.94
BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol (2012) 0.93
Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica (2011) 0.93
Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Thyroid (2014) 0.92
BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract (2012) 0.92
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J (2013) 0.91
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res (2012) 0.90
Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma. Int J Cancer (2014) 0.90
BRAF mutations in acute leukemias. Leukemia (2004) 0.89
Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res (2010) 0.88
Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol (2013) 0.87
Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol (Oxf) (2011) 0.87
BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.87
BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. J Surg Oncol (2014) 0.86
Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. J Transl Med (2014) 0.85
Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med (2015) 0.84
Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol (2013) 0.84
Clinical features and diagnosis of hairy cell leukemia. Best Pract Res Clin Haematol (2015) 0.84
BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol (2014) 0.83
Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology (2012) 0.83
Expression and role of phosphodiesterase 5 in human malignant melanoma cell line. Anticancer Res (2010) 0.82
Molecular and histologic considerations in the assessment of serrated polyps. Arch Pathol Lab Med (2015) 0.82
BRAF Mutation in Hairy Cell Leukemia. Oncol Rev (2014) 0.81
Regulation of monocarboxylate transporter 1 in skeletal muscle cells by intracellular signaling pathways. Biol Pharm Bull (2010) 0.80
Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype. Int J Lab Hematol (2012) 0.80
Erdheim-Chester disease: an orphan condition seeking treatment. Isr Med Assoc J (2012) 0.80